Nuvation Bio Inc.
General ticker "NUVB" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $1.9B (TTM average)
Nuvation Bio Inc. follows the US Stock Market performance with the rate: 13.2%.
Estimated limits based on current volatility of 2.9%: low 4.57$, high 4.84$
Factors to consider:
- Total employees count: 298 (+35.5%) as of 2025
- China accounted for 66.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: IBTROZI commercialization failure, Economic downturns and volatility, Need additional capital, Regulatory and compliance, Intellectual property risks
- Current price 11.5% below estimated low
- Earnings for 6 months up through Q2 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [5.03$, 12.29$]
- 2026-12-31 to 2027-12-31 estimated range: [3.74$, 9.28$]
Financial Metrics affecting the NUVB estimates:
- Positive: with PPE of -15.4 at the end of fiscal year the price was neutral
- Negative: negative Operating income
- Negative: negative Operating cash flow
- Negative: negative Net income
- Negative: Inventory ratio change, % of 73.90 > 4.02
- Negative: 0.33 < Interest expense per share per price, % of 0.43
- Negative: negative Industry operating income (median)
- Negative: negative Industry operating cash flow (median)
- Negative: Industry earnings per price (median), % of -15.99 <= 0
Short-term NUVB quotes
Long-term NUVB plot with estimates
Financial data
| YTD | 2023-12-31 | 2024-12-31 | 2025-12-31 |
|---|---|---|---|
| Operating Revenue | $0.00MM | $7.87MM | $62.90MM |
| Operating Expenses | $99.82MM | $600.50MM | $275.97MM |
| Operating Income | $-99.82MM | $-592.63MM | $-213.06MM |
| Non-Operating Income | $24.02MM | $24.69MM | $8.44MM |
| Interest Expense | $0.00MM | $0.34MM | $13.68MM |
| R&D Expense | $71.29MM | $524.19MM | $115.11MM |
| Income(Loss) | $-75.80MM | $-567.94MM | $-204.63MM |
| Net Income(Loss)* | $-75.80MM | $-567.94MM | $-204.63MM |
| Stockholders Equity | $605.12MM | $463.79MM | $305.72MM |
| Inventory | $0.00MM | $0.00MM | $11.41MM |
| Assets | $621.48MM | $540.63MM | $594.82MM |
| Operating Cash Flow | $-68.00MM | $-130.41MM | $-173.43MM |
| Capital expenditure | $0.07MM | $0.16MM | $0.35MM |
| Investing Cash Flow | $8.92MM | $122.70MM | $99.52MM |
| Financing Cash Flow | $0.63MM | $0.33MM | $202.53MM |
| Earnings Per Share** | $-0.35 | $-2.11 | $-0.60 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.